Annexon Biosciences to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel complement therapies for neuroinflammatory diseases, has announced its participation in two upcoming investor conferences in September 2024. Douglas Love, the company's president and CEO, will engage in fireside chats at the following events:

1. Wells Fargo Healthcare Conference on September 4, 2024, at 9:30 a.m. ET in Boston, MA
2. Cantor Global Healthcare Conference on September 17, 2024, at 3:05 p.m. ET in New York, NY

Live webcasts of both presentations will be available on the Annexon website under the 'Events & Presentations' section of the Investors page. Replays will be archived for 30 days following each presentation.

BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

• Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 9:30 a.m. ET in Boston, MA; and,
• Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 3:05 p.m. ET in New York, NY.

Live webcasts of the presentations can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon’s novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:

Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

FAQ

When is Annexon Biosciences (ANNX) participating in the Wells Fargo Healthcare Conference?

Annexon Biosciences (ANNX) is participating in the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 9:30 a.m. ET in Boston, MA.

What time is Annexon Biosciences (ANNX) presenting at the Cantor Global Healthcare Conference?

Annexon Biosciences (ANNX) is presenting at the Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 3:05 p.m. ET in New York, NY.

Who will represent Annexon Biosciences (ANNX) at the September 2024 investor conferences?

Douglas Love, Esq., president and chief executive officer of Annexon Biosciences (ANNX), will represent the company at the September 2024 investor conferences.

How can investors access Annexon Biosciences (ANNX) presentations from the September 2024 conferences?

Investors can access live webcasts of Annexon Biosciences (ANNX) presentations under the 'Events & Presentations' section on the Investors page at www.annexonbio.com. Replays will be available for 30 days after each presentation.